← Back to Search

18F-FAZA PET Scan for Lung Cancer

N/A

Recruiting

Led By Alex Sun, MD

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is looking to see if a PET scan can show low levels of oxygen in lung cancer, which may help to show how the cancer responds to treatment.

Who is the study for?

This trial is for adults over 18 with stage II or III lung cancer who are set to receive radiotherapy. It's open to those with both non-small cell (NSCLC) and small cell lung cancer (SCLC), even if they're getting other treatments too. Women must test negative for pregnancy before the PET scan, and all participants need to be able to lie on their back for an hour and give written consent.Check my eligibility

What is being tested?

The study tests a PET scan using a tracer called FAZA that detects low oxygen levels in tumors, which can affect how well cancer responds to treatment. Participants will have one FAZA PET scan before starting radiotherapy, aiming to see if this method offers better insights into tumor hypoxia than current techniques.See study design

What are the potential side effects?

While the description doesn't list specific side effects of FAZA, similar radiotracers used in PET scans may cause temporary discomfort at the injection site, allergic reactions, or rare changes in blood sugar levels.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Malignant Neoplasms

Number of patients with lung cancer using the PET tracer FAZA to image primary tumor hypoxia prior to treatment with radiotherapy

Secondary outcome measures

Proportion of the volume of injected FAZA tracer taken up in the tumor prior to treatment with radiotherapy

Trial Design

1Treatment groups

Experimental Treatment

Group I: 18-F-FAZA ScanExperimental Treatment1 Intervention

All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,472 Previous Clinical Trials

484,984 Total Patients Enrolled

Alex Sun, MDPrincipal InvestigatorThe Princess Margaret Cancer Foundation

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has recruitment for this clinical experiment commenced?

"According to the clinicaltrials.gov website, this medical trial is still enrolling patients. The study was first published on 12th December 2014 and was amended as recently as 6th October 2022."

Answered by AI

What is the participant population size of this investigation?

"Affirmative. Per the information posted on clinicaltrials.gov, this experiment is presently accepting applicants. It was first advertised in December 2014 and was most recently updated October 2022; they are looking to engage 20 participants at a single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer

2014. "18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02701699.